CY1109143T1 - Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας - Google Patents
Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτηταςInfo
- Publication number
- CY1109143T1 CY1109143T1 CY20091100617T CY091100617T CY1109143T1 CY 1109143 T1 CY1109143 T1 CY 1109143T1 CY 20091100617 T CY20091100617 T CY 20091100617T CY 091100617 T CY091100617 T CY 091100617T CY 1109143 T1 CY1109143 T1 CY 1109143T1
- Authority
- CY
- Cyprus
- Prior art keywords
- areas
- immunoglobulin
- modified
- epitope
- moral
- Prior art date
Links
- 238000003287 bathing Methods 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 9
- 102000018358 immunoglobulin Human genes 0.000 abstract 9
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
Μέθοδος διαμόρφωσης μιας ανοσοσφαιρίνης που περιλαμβάνει τουλάχιστον μία τροποποίηση σε μία περιοχή δομικού βρόγχου της εν λόγω ανοσοσφαιρίνης και προσδιορισμού της δέσμευσης της εν λόγω ανοσοσφαιρίνης σε ένα επίτοπο ενός αντιγόνου, όπου η μη τροποποιημένη ανοσοσφαιρίνη δεν δεσμεύεται σημαντικά στο εν λόγω επίτοπο, που περιλαμβάνει τα στάδια των: - παροχής ενός νουκλεϊνικού οξέος που κωδικοποιεί μία ανοσοσφαιρίνη που περιλαμβάνει τουλάχιστον μία περιοχή δομικού βρόγχου, - τροποποίησης τουλάχιστον ενός κατάλοιπου νουκλεοτιδίου τουλάχιστον μίας εκ των εν λόγω περιοχών δομικού βρόγχου, - μεταφοράς του εν λόγω νουκλεϊνικού οξέος σε ένα σύστημα έκφρασης, - έκφρασης της εν λόγω τροποποιημένης ανοσοσφαιρίνης, - επαφής της εκφρασμένης τροποποιημένης ανοσοσφαιρίνης με ένα επίτοπο, και - προσδιορισμού εάν η εν λόγω τροποποιημένη ανοσοσφαιρίνη δεσμεύεται στο εν λόγω επίτοπο, καθώς επίσης και τροποποιημένες ανοσοσφαιρίνες.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64114405P | 2005-01-05 | 2005-01-05 | |
EP06703578A EP1699826B1 (en) | 2005-01-05 | 2006-01-05 | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109143T1 true CY1109143T1 (el) | 2014-07-02 |
Family
ID=36445146
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100172T CY1108767T1 (el) | 2005-01-05 | 2009-02-18 | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενης σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας |
CY20091100528T CY1110895T1 (el) | 2005-01-05 | 2009-05-18 | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας |
CY20091100617T CY1109143T1 (el) | 2005-01-05 | 2009-06-11 | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100172T CY1108767T1 (el) | 2005-01-05 | 2009-02-18 | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενης σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας |
CY20091100528T CY1110895T1 (el) | 2005-01-05 | 2009-05-18 | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας |
Country Status (23)
Country | Link |
---|---|
US (8) | US20090298195A1 (el) |
EP (4) | EP2028193B1 (el) |
JP (3) | JP4937138B2 (el) |
KR (2) | KR101404512B1 (el) |
CN (2) | CN101098891B (el) |
AT (4) | ATE414718T1 (el) |
AU (1) | AU2006204459B2 (el) |
BR (1) | BRPI0606399A8 (el) |
CA (1) | CA2594356C (el) |
CY (3) | CY1108767T1 (el) |
DE (3) | DE602006005526D1 (el) |
DK (4) | DK2028193T3 (el) |
EA (1) | EA018897B1 (el) |
ES (4) | ES2320374T3 (el) |
HR (3) | HRP20090087T3 (el) |
IL (1) | IL184103A (el) |
MX (1) | MX2007008118A (el) |
NZ (1) | NZ555893A (el) |
PL (3) | PL1699826T3 (el) |
PT (4) | PT2028193E (el) |
RS (3) | RS50785B (el) |
SI (3) | SI1699826T1 (el) |
WO (1) | WO2006072620A1 (el) |
Families Citing this family (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0516011A (pt) | 2004-09-24 | 2008-08-19 | Amgen Inc | moléculas fc modificadas |
KR101404512B1 (ko) | 2005-01-05 | 2015-01-29 | 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. | 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을갖는 합성 면역글로불린 영역 |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
AT503902B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
EP1975178A1 (en) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
WO2008124858A2 (en) * | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
EP2160406B1 (en) | 2007-05-24 | 2013-10-02 | Baxter Healthcare SA | Antibodies useful for therapy and diagnosis of cancer |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
PH12018501459A1 (en) | 2007-09-26 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
WO2009088805A2 (en) * | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
AU2014200215B2 (en) * | 2008-01-31 | 2016-09-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
AU2009212747B2 (en) * | 2008-01-31 | 2013-11-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
MX338825B (es) | 2008-10-02 | 2016-05-03 | Emergent Product Dev Seattle | Proteinas de enlace a objetivos multiples de antagonistas de cd86. |
WO2010078916A1 (en) | 2008-12-19 | 2010-07-15 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
CN101609096B (zh) * | 2009-07-21 | 2012-11-07 | 上海师范大学 | 肺癌标志物检测免疫层析试纸的制备方法 |
ES2712997T3 (es) | 2009-08-05 | 2019-05-17 | Philogen Spa | Selección como diana de neovasculatura de médula ósea |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
PT2519543T (pt) | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
US20130189247A1 (en) * | 2010-02-12 | 2013-07-25 | Research Corporation Technologies, Inc. | Multimeric Proteins Comprising Immunoglobulin Constant Domains |
EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
JP2014500879A (ja) | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bcma発現に相関性を有する疾患を治療する因子及び方法 |
MX2013007067A (es) | 2010-12-20 | 2013-11-01 | Medimmune Ltd | Anticuerpos anti-il-18 y sus usos. |
US9156917B2 (en) | 2011-02-11 | 2015-10-13 | Research Corporation Technologies, Inc. | CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds |
AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US9890218B2 (en) | 2011-06-30 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
KR102208698B1 (ko) * | 2011-12-21 | 2021-01-29 | 암젠 인크 | 신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드 |
EP3447071A1 (en) * | 2012-01-09 | 2019-02-27 | Pfizer Healthcare Ireland | Mutant antibodies and conjugation thereof |
CN102585000B (zh) * | 2012-02-22 | 2013-05-29 | 尉军 | 一种肿瘤标志物cd25自身抗体及应用 |
US9676857B2 (en) | 2012-03-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble engineered monomeric Fc |
CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
EP2855520B1 (en) * | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
JP6628966B2 (ja) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
CA2882272C (en) | 2012-08-24 | 2023-08-29 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc region variant |
US9834598B2 (en) | 2012-10-15 | 2017-12-05 | Medimmune Limited | Antibodies to amyloid beta |
PT2928921T (pt) | 2012-12-05 | 2021-04-06 | Novartis Ag | Composições e métodos para anticorpos que visam epo |
ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
EP2953974B1 (en) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and bcma |
WO2014152832A1 (en) | 2013-03-14 | 2014-09-25 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
WO2014144600A2 (en) | 2013-03-15 | 2014-09-18 | Viktor Roschke | Multivalent and monovalent multispecific complexes and their uses |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
WO2014145907A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
MY172430A (en) | 2013-04-29 | 2019-11-25 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
KR101800295B1 (ko) | 2013-09-04 | 2017-12-20 | 엘지디스플레이 주식회사 | 위치감지방법, 위치감지장치, 안테나 장치 및 디스플레이 장치 |
GB201317622D0 (en) * | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
KR20160079854A (ko) | 2013-10-31 | 2016-07-06 | 프레드 헛친슨 켄서 리서치 센터 | 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도 |
CA2929044A1 (en) | 2013-11-11 | 2015-05-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified antibody variable region |
DK3083671T3 (da) | 2013-12-20 | 2020-12-07 | Hutchinson Fred Cancer Res | Mærkede kimære effektormolekyler og receptorer deraf |
EP3842455A1 (en) | 2014-01-15 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with improved protein a-binding |
CA2943167A1 (en) * | 2014-03-24 | 2015-10-01 | University Of Southampton | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
SG10202008629XA (en) | 2014-03-28 | 2020-10-29 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
AU2015283704A1 (en) | 2014-07-01 | 2016-12-15 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
TWI679259B (zh) | 2014-08-11 | 2019-12-11 | 德商漢高智慧財產控股公司 | 光學透明的熱熔黏著劑及其用途 |
JP6708635B2 (ja) | 2014-10-09 | 2020-06-10 | エンクマフ エスアーエールエル | CD3εおよびROR1に対する二特異性抗体 |
TW202313697A (zh) | 2014-11-11 | 2023-04-01 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
IL252480B2 (en) | 2014-11-26 | 2023-12-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and tumor antigens |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
US10982008B2 (en) | 2014-12-05 | 2021-04-20 | Merck Patent Gmbh | Domain-exchanged antibody |
PL3234107T3 (pl) | 2014-12-19 | 2023-01-16 | Immusoft Corporation | Limfocyty b do dostarczania in vivo środków terapeutycznych |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
CA2978186A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
US20180355318A1 (en) | 2015-04-29 | 2018-12-13 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
BR112018001955B1 (pt) | 2015-08-03 | 2021-05-11 | Engmab Sárl | anticorpo monoclonal que se liga às células b humanas (bcma), composição farmacêutica e seu uso |
US20180230540A1 (en) | 2015-08-12 | 2018-08-16 | Novartis Ag | Methods of treating ophthalmic disorders |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
MX2018004071A (es) | 2015-10-05 | 2018-11-09 | Fredax Ab | Polipeptidos como anticuerpos y usos de los mismos. |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
CN109069539A (zh) | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
US10982136B2 (en) | 2016-02-26 | 2021-04-20 | The Regents Of The University Of California | Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters |
CN105664157A (zh) * | 2016-03-11 | 2016-06-15 | 江苏亲合力病毒检测工程有限公司 | 一种抗巨细胞病毒人源化抗体药物 |
WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
CN109195630A (zh) | 2016-03-15 | 2019-01-11 | 阿斯利康(瑞典)有限公司 | 用于治疗与淀粉样蛋白β累积相关的病症的BACE抑制剂和抗体或抗原结合片段的组合 |
CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
KR102542533B1 (ko) | 2016-04-14 | 2023-06-13 | 프레드 허친슨 캔서 센터 | 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US10544221B2 (en) | 2016-05-20 | 2020-01-28 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
CA3027612A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
JP2019532017A (ja) | 2016-07-14 | 2019-11-07 | フレッド ハッチンソン キャンサー リサーチ センター | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Il−8関連疾患の治療用又は予防用組成物 |
US11235076B2 (en) | 2016-08-29 | 2022-02-01 | Fred Hutchinson Cancer Research Center | Chelating platform for delivery of radionuclides |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3509595B1 (en) | 2016-09-06 | 2022-11-02 | The Regents of The University of California | Formulations of hydroxypyridonate actinide/lanthanide decorporation agents |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP4290532A3 (en) | 2016-09-29 | 2024-03-20 | The Regents of the University of California | Separation of metal ions by liquid-liquid extraction |
AU2017342559B2 (en) | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
WO2018098354A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
WO2018106993A1 (en) * | 2016-12-09 | 2018-06-14 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Tlr9-binding chimeric antigen receptors |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
IL268349B1 (en) | 2017-02-17 | 2024-04-01 | Hutchinson Fred Cancer Res | Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders |
EP3583120B1 (en) | 2017-02-17 | 2022-10-05 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 酵素補充療法用酵素を含む融合タンパク質 |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3082383A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137 |
CA3084551A1 (en) | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Daric interleukin receptors |
WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
SG11202009010RA (en) | 2018-03-15 | 2020-10-29 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US10633458B2 (en) | 2018-04-10 | 2020-04-28 | Y-Biologics Inc. | Cell engaging binding molecules |
US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
WO2019222278A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Dual binding moiety |
KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
CN112584862A (zh) * | 2018-05-17 | 2021-03-30 | 伊米若梅有限公司 | Ch3结构域表位标签 |
GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
BR112021000282A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a cd137 e ox40 |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
CA3106046A1 (en) | 2018-07-12 | 2020-01-16 | F-Star Beta Limited | Antibody molecules that bind pd-l1 and cd137 |
GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
CN112839960A (zh) | 2018-08-10 | 2021-05-25 | 中外制药株式会社 | 抗cd137抗原结合分子及其应用 |
EP4268831A3 (en) | 2018-09-12 | 2024-05-22 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
WO2020060593A1 (en) * | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Conditionally active receptors |
IL297931A (en) | 2018-09-25 | 2023-01-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
US20220010016A1 (en) | 2018-10-17 | 2022-01-13 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
SG11202109406TA (en) | 2019-03-01 | 2021-09-29 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3 |
SG11202110986YA (en) | 2019-04-10 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Method for purifying fc region-modified antibody |
AU2020298572A1 (en) | 2019-07-02 | 2021-11-18 | Fred Hutchinson Cancer Center | Recombinant Ad35 vectors and related gene therapy improvements |
CN112898412A (zh) * | 2019-12-03 | 2021-06-04 | 复旦大学 | 一种高稳定性类Fab抗体及其制备方法和应用 |
KR20220113791A (ko) | 2019-12-18 | 2022-08-16 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ccl2 항체 |
CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
US20230058982A1 (en) | 2019-12-27 | 2023-02-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody and use thereof |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
AU2021250186A1 (en) | 2020-03-31 | 2022-12-01 | Chugai Seiyaku Kabushiki Kaisha | DLL3-targeting multispecific antigen-binding molecules and uses thereof |
KR20230005952A (ko) | 2020-05-04 | 2023-01-10 | 임뮤노라이즌 엘티디. | 전구체 삼중-특이적 항체 구조체 및 그의 이용 방법 |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
AU2021327387A1 (en) | 2020-08-21 | 2023-05-04 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
WO2022044248A1 (ja) | 2020-08-28 | 2022-03-03 | 中外製薬株式会社 | ヘテロ二量体Fcポリペプチド |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
CA3217220A1 (en) * | 2021-04-19 | 2022-10-27 | Janssen Biotech, Inc. | Molecules with engineered antibody constant region variants |
EP4333900A2 (en) | 2021-05-03 | 2024-03-13 | Merck Patent GmbH | Her2 targeting fc antigen binding fragment-drug conjugates |
CN117999101A (zh) | 2021-05-25 | 2024-05-07 | 默克专利股份公司 | 靶向EGFR的Fc抗原结合片段-药物缀合物 |
EP4355775A1 (en) | 2021-06-18 | 2024-04-24 | F. Hoffmann-La Roche AG | Bispecific anti-ccl2 antibodies |
IL309115A (en) | 2021-06-25 | 2024-02-01 | Chugai Pharmaceutical Co Ltd | Anti-CTLA-4 antibodies |
TW202311291A (zh) | 2021-06-25 | 2023-03-16 | 日商中外製藥股份有限公司 | 抗ctla-4抗體的用途 |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
WO2024042104A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor |
WO2024042105A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0570027B1 (en) | 1984-03-01 | 1999-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | T cell receptor-specific for antigen polypeptides and related polynucleotides |
EP1186660A3 (fr) * | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
US5763192A (en) * | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5892019A (en) * | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JP3283041B2 (ja) | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5395750A (en) * | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
AU675223B2 (en) | 1992-05-08 | 1997-01-30 | Creative Biomolecules, Inc. | Chimeric multivalent protein analogues and methods of use thereof |
DE69334287D1 (de) * | 1992-09-25 | 2009-07-09 | Avipep Pty Ltd | Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist |
US6194166B1 (en) * | 1993-05-24 | 2001-02-27 | Takara Shuzo Co., Ltd. | Gene regulating aureobasidin sensitivity |
US5536814A (en) | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
AU701302B2 (en) * | 1994-05-13 | 1999-01-21 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Improvements in or relating to peptide delivery |
GB9501079D0 (en) | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
AUPO591797A0 (en) * | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6352842B1 (en) * | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6361974B1 (en) * | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
US6358709B1 (en) * | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6477506B1 (en) * | 1998-02-23 | 2002-11-05 | Sony Corporation | Terminal apparatus, information service center, transmitting system, and transmitting method |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6180343B1 (en) * | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6376246B1 (en) * | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
EP1130093A1 (en) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
EP1165757A1 (en) * | 1999-03-05 | 2002-01-02 | Maxygen, Inc. | Encryption of traits using split gene sequences |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
WO2001001748A2 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Peptide compounds that bind her2 |
DK1247095T3 (da) | 1999-12-06 | 2008-12-08 | Univ Illinois | TCR-proteiner med höj affinitet samt fremgangsmåder |
EP1118661A1 (en) | 2000-01-13 | 2001-07-25 | Het Nederlands Kanker Instituut | T cell receptor libraries |
JP2003274960A (ja) | 2000-02-03 | 2003-09-30 | Japan Science & Technology Corp | 可溶性t細胞受容体タンパク質およびその作成方法 |
EP1259601A2 (en) | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
WO2001070947A2 (en) | 2000-03-20 | 2001-09-27 | Maxygen, Inc. | Method for generating recombinant dna molecules in complex mixtures |
AU5943201A (en) * | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
AU2001261628A1 (en) | 2000-05-16 | 2001-11-26 | Euroceltique S.A. | Cd28 synthebody for the modulation of immune responses |
JP2004511430A (ja) * | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | 二重特異性免疫グロブリン様抗原結合蛋白および製造方法 |
US6406863B1 (en) | 2000-06-23 | 2002-06-18 | Genetastix Corporation | High throughput generation and screening of fully human antibody repertoire in yeast |
AU2001273559A1 (en) | 2000-07-18 | 2002-01-30 | Enchira Biotechnology Corporation | Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids |
JP2002058479A (ja) | 2000-08-14 | 2002-02-26 | Canon Inc | 構造認識アミノ酸配列の取得方法 |
EP2141243A3 (en) * | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US20040082508A1 (en) * | 2000-11-08 | 2004-04-29 | Henry Yue | Secreted proteins |
GB0029407D0 (en) * | 2000-12-01 | 2001-01-17 | Affitech As | Product |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
IL141539A0 (en) | 2001-02-20 | 2002-03-10 | Yeda Res & Dev | Dna molecules and cells transfected therewith |
US20030157561A1 (en) * | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20030082630A1 (en) * | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
EP1281757A1 (en) | 2001-07-31 | 2003-02-05 | Direvo Biotech AG | Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids |
DE60203125T2 (de) | 2001-08-31 | 2006-04-06 | Avidex Ltd., Abingdon | Löslicher t zell rezeptor |
WO2003029456A1 (en) | 2001-10-01 | 2003-04-10 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
ES2384235T3 (es) | 2001-10-22 | 2012-07-02 | The Scripps Research Institute | Compuestos dirigidos a integrinas |
US20040043424A1 (en) * | 2001-11-15 | 2004-03-04 | Baughn Mariah R | Immunoglobulin superfamily proteins |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
US20040063924A1 (en) * | 2002-01-28 | 2004-04-01 | Y Tom Tang | Secreted proteins |
US20030157091A1 (en) * | 2002-02-14 | 2003-08-21 | Dyax Corporation | Multi-functional proteins |
EP1482984A4 (en) * | 2002-02-19 | 2006-12-20 | Syntherica Corp | REPLACEMENT ANTIBODIES AND METHOD FOR THEIR MANUFACTURE AND USE |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003213687A1 (en) | 2002-03-04 | 2003-09-22 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
US20040097711A1 (en) * | 2002-03-12 | 2004-05-20 | Henry Yue | Immunoglobulin superfamily proteins |
EP1394251A1 (en) | 2002-08-23 | 2004-03-03 | Direvo Biotech AG | Method for the selective randomization of polynucleotides |
NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
ATE432290T1 (de) | 2002-11-09 | 2009-06-15 | Immunocore Ltd | T ZELL REZEPTOR ßDISPLAYß |
JP2006523437A (ja) | 2002-12-03 | 2006-10-19 | アヴィデックス リミテッド | レセプター複合体 |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2005021595A1 (en) | 2003-08-28 | 2005-03-10 | Euro-Celtique S.A. | Methods of antibody engineering using antibody display rules |
CA2550551C (en) | 2004-01-16 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
EP1737890A2 (en) * | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP1765860B1 (en) | 2004-05-19 | 2008-12-10 | MediGene Ltd. | High affinity ny-eso t cell receptor |
DE602005009825D1 (de) | 2004-05-19 | 2008-10-30 | Medigene Ltd | Verfahren zur verbesserung von t-zellrezeptoren |
GB0411773D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex |
KR20070038557A (ko) | 2004-07-22 | 2007-04-10 | 제넨테크, 인크. | Her2 항체 조성물 |
BRPI0516011A (pt) | 2004-09-24 | 2008-08-19 | Amgen Inc | moléculas fc modificadas |
JP2008514685A (ja) | 2004-10-01 | 2008-05-08 | メディジーン リミテッド | 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するt細胞レセプター |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
US20080274133A1 (en) | 2004-11-18 | 2008-11-06 | Avidex Ltd. | Soluble Bifunctional Proteins |
GB0425732D0 (en) | 2004-11-23 | 2004-12-22 | Avidex Ltd | Gamma-delta t cell receptors |
KR101404512B1 (ko) | 2005-01-05 | 2015-01-29 | 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. | 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을갖는 합성 면역글로불린 영역 |
GB0503546D0 (en) | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
CA2648849A1 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals, Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
US7514271B2 (en) | 2007-03-30 | 2009-04-07 | International Business Machines Corporation | Method of forming high density planar magnetic domain wall memory |
EP1975178A1 (en) | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
AU2009212747B2 (en) | 2008-01-31 | 2013-11-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
US20120094874A1 (en) | 2009-07-09 | 2012-04-19 | F-Star Biotechnologische Forschungs-Und Entwicklungsges. M.B.H | Stabilized immunoglobulin constant domains |
US20120010388A1 (en) | 2010-04-16 | 2012-01-12 | Gottfried Himmler | LeY SPECIFIC BIOTHERAPEUTIC |
EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
US20140087957A1 (en) | 2012-09-25 | 2014-03-27 | Marko Vuskovic | Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes |
GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
-
2006
- 2006-01-05 KR KR20077014725A patent/KR101404512B1/ko active IP Right Grant
- 2006-01-05 SI SI200630309T patent/SI1699826T1/sl unknown
- 2006-01-05 EA EA200701443A patent/EA018897B1/ru not_active IP Right Cessation
- 2006-01-05 PL PL06703578T patent/PL1699826T3/pl unknown
- 2006-01-05 AT AT06121439T patent/ATE414718T1/de active
- 2006-01-05 EP EP08168439A patent/EP2028193B1/en active Active
- 2006-01-05 PT PT08168439T patent/PT2028193E/pt unknown
- 2006-01-05 MX MX2007008118A patent/MX2007008118A/es active IP Right Grant
- 2006-01-05 CN CN200680001831.4A patent/CN101098891B/zh active Active
- 2006-01-05 SI SI200630199T patent/SI1752471T1/sl unknown
- 2006-01-05 US US11/722,517 patent/US20090298195A1/en not_active Abandoned
- 2006-01-05 DE DE602006005526T patent/DE602006005526D1/de active Active
- 2006-01-05 JP JP2007549891A patent/JP4937138B2/ja active Active
- 2006-01-05 PT PT06703578T patent/PT1699826E/pt unknown
- 2006-01-05 CN CN201310486561.2A patent/CN103555733A/zh active Pending
- 2006-01-05 DK DK08168439.1T patent/DK2028193T3/da active
- 2006-01-05 DK DK06011173T patent/DK1772465T3/da active
- 2006-01-05 EP EP06121439A patent/EP1752471B9/en active Active
- 2006-01-05 EP EP06011173A patent/EP1772465B1/en active Active
- 2006-01-05 ES ES06121439T patent/ES2320374T3/es active Active
- 2006-01-05 PT PT06121439T patent/PT1752471E/pt unknown
- 2006-01-05 DK DK06703578T patent/DK1699826T3/da active
- 2006-01-05 RS RSP-2009/0212A patent/RS50785B/sr unknown
- 2006-01-05 BR BRPI0606399A patent/BRPI0606399A8/pt not_active Application Discontinuation
- 2006-01-05 AT AT06011173T patent/ATE423140T1/de active
- 2006-01-05 NZ NZ555893A patent/NZ555893A/en unknown
- 2006-01-05 RS RSP-2009/0076A patent/RS50752B/sr unknown
- 2006-01-05 WO PCT/EP2006/050059 patent/WO2006072620A1/en active Application Filing
- 2006-01-05 PL PL06121439T patent/PL1752471T3/pl unknown
- 2006-01-05 EP EP06703578A patent/EP1699826B1/en active Active
- 2006-01-05 AT AT08168439T patent/ATE548386T1/de active
- 2006-01-05 CA CA2594356A patent/CA2594356C/en active Active
- 2006-01-05 DE DE602006005200T patent/DE602006005200D1/de active Active
- 2006-01-05 RS RSP-2009/0267A patent/RS50830B/sr unknown
- 2006-01-05 KR KR1020137018696A patent/KR20130105885A/ko not_active Application Discontinuation
- 2006-01-05 PT PT06011173T patent/PT1772465E/pt unknown
- 2006-01-05 ES ES06011173T patent/ES2321861T3/es active Active
- 2006-01-05 PL PL06011173T patent/PL1772465T3/pl unknown
- 2006-01-05 DK DK06121439T patent/DK1752471T3/da active
- 2006-01-05 SI SI200630280T patent/SI1772465T1/sl unknown
- 2006-01-05 ES ES06703578T patent/ES2323651T3/es active Active
- 2006-01-05 DE DE602006003695T patent/DE602006003695D1/de active Active
- 2006-01-05 AU AU2006204459A patent/AU2006204459B2/en active Active
- 2006-01-05 ES ES08168439T patent/ES2384039T3/es active Active
- 2006-01-05 AT AT06703578T patent/ATE425186T1/de active
-
2007
- 2007-06-21 IL IL184103A patent/IL184103A/en active IP Right Grant
-
2009
- 2009-02-12 HR HR20090087T patent/HRP20090087T3/xx unknown
- 2009-02-18 CY CY20091100172T patent/CY1108767T1/el unknown
- 2009-04-20 HR HR20090228T patent/HRP20090228T1/xx unknown
- 2009-05-18 CY CY20091100528T patent/CY1110895T1/el unknown
- 2009-06-02 HR HR20090326T patent/HRP20090326T1/xx unknown
- 2009-06-11 CY CY20091100617T patent/CY1109143T1/el unknown
-
2011
- 2011-05-31 US US13/149,871 patent/US9856311B2/en active Active
- 2011-06-01 US US13/151,195 patent/US9045528B2/en active Active
- 2011-06-01 US US13/151,207 patent/US20110251375A1/en not_active Abandoned
- 2011-12-19 JP JP2011277069A patent/JP5483294B2/ja active Active
-
2013
- 2013-12-17 JP JP2013260218A patent/JP5717833B2/ja active Active
-
2017
- 2017-03-31 US US15/476,029 patent/US10385118B2/en active Active
-
2019
- 2019-04-16 US US16/386,067 patent/US11084868B2/en active Active
- 2019-11-22 US US16/692,220 patent/US11499249B2/en active Active
-
2022
- 2022-10-11 US US17/963,509 patent/US20230340696A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109143T1 (el) | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας | |
CY1119641T1 (el) | Μεθοδοι κατασκευης ανοσοσφαιρινων | |
CY1121294T1 (el) | Αντι-ilt7 αντισωμα | |
CY1117963T1 (el) | Αντισωματα που προσδενουν τα il-17a και il-17f | |
CY1125133T1 (el) | Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17 | |
CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
CY1120412T1 (el) | Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31 | |
CY1122412T1 (el) | Ομοιοπολικα διασωματα καi χρησεις αυτων | |
CY1120640T1 (el) | Πεπτιδια σχετιζομενα me tcr-v-bhta για θεραπευτικη αγωγη και διαγνωση αυτοανοσης ασθενειας | |
CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
CY1123275T1 (el) | Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων | |
EA200970556A1 (ru) | Моноклональные антитела против angptl3 | |
CY1114603T1 (el) | ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ | |
CY1124849T1 (el) | Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων | |
CY1112288T1 (el) | Θεραπεια του καρκινου με αντισωματα κατα της il-1a | |
CY1119890T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1 | |
EA201001335A1 (ru) | Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение | |
CY1121167T1 (el) | Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων | |
CY1118244T1 (el) | Αντισωματα κατα της il-25 | |
CY1118918T1 (el) | Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης | |
CY1115927T1 (el) | Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2 | |
CY1120326T1 (el) | Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους | |
NZ591488A (en) | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use | |
CY1124642T1 (el) | Εξανθρωπισμος αντισωματων κονικλου χρησιμοποιωντας εναν καθολικο σκελετο αντισωματος |